Enterprise Value
3.138B
Cash
213.4M
Avg Qtr Burn
-49.05M
Short % of Float
7.46%
Insider Ownership
4.49%
Institutional Own.
66.87%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Plozasiran (ARO-APOC3) Details Familial chylomicronemia syndrome Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
Fazirsiran (ARO-AAT) (TAK-999) Details Severe alpha-1 antitrypsin deficiency, Liver disease | Phase 3 Update | |
Plozasiran (ARO-APOC3) Details Severe hypertriglyceridemia | Phase 3 Initiation | |
Plozasiran (ARO-APOC3) Details Dyslipidemia | Phase 2b Update | |
Zodasiran (ARO-ANG3) Details Dyslipidemia | Phase 2b Update | |
ARO-ANG3 Details Dyslipidemia | Phase 2 Update | |
ARO-DM1 Details Myotonic Dystrophy Type 1 | Phase 1/2 Data readout | |
ARO-CFB Details Complement mediated diseases, Kidney disease, IgA nephropathy | Phase 1/2 Data readout | |
ARO-C3 (RNAi) Details Renal disease, Paroxysmal nocturnal hemoglobinuria | Phase 1/2 Data readout | |
ARO-MMP7 Details Idiopathic pulmonary fibrosis | Phase 1/2 Data readout | |
ARO-MUC5AC Details Lung disease, Muco-Obstructive Lung Diseases | Phase 1/2 Data readout | |
ARO-RAGE Details Muco-Obstructive Lung Diseases, Inflammatory disease, Asthma | Phase 1/2 Data readout | |
ARO-DUX4 Details Facioscapulohumeral muscular dystrophy | Phase 1/2 Initiation | |
JNJ-3989 (ARO-HBV) Details Hepatitis B | Failed Discontinued | |
ARO-HSD Details Liver disease, Non-alcoholic steatohepatitis | Failed Discontinued |